

A list of all abbreviations and terms appearing in this issue of *Therapy*

AS	Active surveillance	ESA	Erythropoiesis-stimulating agents	PR	Partial response
ASTRO	American Society for Therapeutic Radiology and Oncology	EPO	Erythropoietin	PTI	Percent tumor involvement
AR	androgen receptor	ECE	Extracapsular extension	PTEN	Phosphatase and tensin homolog
AIPC	androgen-independent prostate cancer	GAT	General appearance teasing	PDGF	Platelet-derived growth factor
ACORD	Anemia CORrection in Diabetes	GLP	Glucagon-like peptide	PFS	Progression-free survival
AN	Anorexia nervosa	GIP	Glucose-dependent insulinotropic polypeptide	PCa	Prostate cancer
APC	Antigen-presenting cell	GnRH	Gonadotropin-releasing hormone	PSA	Prostate-specific antigen
ATA	Atmosphere absolute	Hb	Hemoglobin	PAP	Prostatic acid phosphatase
BED	Binge eating disorder	HIFU	High intensity focused ultrasound	PRCA	Pure red cell aplasia
BMD	Bone mineral density	HBOT	Hyperbaric oxygen therapy	QoL	Quality of life
CALGB	Cancer and leukemia group B	IL-6	Interleukin-6	RP	Radical prostatectomy
CVD	Cardiovascular disease	LAC	Laser-assisted cryotherapy	RANKL	RANK ligand
CRPC	Castrate-resistant prostate cancer	LVH	Left ventricular hypertrophy	RANK	Receptor activator of nuclear factor-B
CDC	Center for disease control and prevention	LVMI	Left ventricular mass index	R-Smads	Receptor-regulated Smads
CBT	Cognitive behavioural therapy	LUTS	Lower urinary tract symptoms	rHuEPO	Recombinant human erythropoietin
CLI	Critical limb ischemia	MRI	Magnetic resonance imaging	TcpO2	Transcutaneous partial oxygen pressure
DC	Dendritic cell	MHC	Major histocompatibility complexes	TGF- $\alpha$ 1	Transforming growth factor- $\alpha$ 1
DSM	Diagnostic and Statistical Manual Of Mental Disorders	MTD	Maximum tolerated dose	TGF- $\beta$ 1	Transforming growth factor- $\beta$ 1
DOPPS	Dialysis outcomes and practice patterns	mTHPC	Meso tetra hydroxy phenyl chlorin	TNF- $\alpha$	Tumor necrosis factor- $\alpha$
DPP	Dipeptidyl peptidase	NCIC CTG	National Cancer Institute of Canada Clinical Trials Group	TRAIL	Tumor necrosis factor-related apoptosis-inducing ligand
DT	Doubling time	NO	Nitric oxide	VTP	Vascular-targeted photodynamic
EDNOS	Eating disorder not otherwise specified	OPG	Osteoprotegerin	WST	Weight and size teasing
		OS	Overall survival .		
		PTH	Parathyroid hormone		
		pO <sub>2</sub>	Partial oxygen pressure		